Azitra is developing ATR04-484 for the treatment of EGFR inhibitor-associated rash with plans to dose first patient in Phase 1/2 trial in the first half of 2025 "We look forward to presenting an ...
The MarketWatch News Department was not involved in the creation of this content. ATR-01, which uses a filaggrin-secreting strain of S. epidermidis, is in preclinical development for ichthyosis ...
BRANFORD, Conn., Aug. 27, 2025 /PRNewswire/ -- Azitra, Inc. (AZTR) ("Azitra"), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today ...
Azitra (AZTR) is developing ATR04-484 for the treatment of EGFR inhibitor-associated rash with plans to dose first patient in Phase 1/2 trial in the first half of 2025 BRANFORD, Conn., April 25, 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results